AbbVie Inc. $ABBV Shares Purchased by Mirabella Financial Services LLP

Mirabella Financial Services LLP boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 154.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,899 shares of the company’s stock after buying an additional 19,980 shares during the period. AbbVie accounts for 0.6% of Mirabella Financial Services LLP’s investment portfolio, making the stock its 29th largest position. Mirabella Financial Services LLP’s holdings in AbbVie were worth $7,602,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the stock. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the 2nd quarter worth $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter valued at about $26,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the third quarter worth about $31,000. Caitlin John LLC purchased a new position in AbbVie during the third quarter worth about $33,000. Finally, Financial Gravity Companies Inc. acquired a new position in AbbVie in the 2nd quarter valued at about $36,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ABBV shares. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Evercore decreased their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Guggenheim reissued a “buy” rating on shares of AbbVie in a research note on Thursday. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $221.54 on Tuesday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a market capitalization of $391.72 billion, a PE ratio of 93.87, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. The stock’s 50-day simple moving average is $224.35 and its 200-day simple moving average is $224.89.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.08% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.